Dr Reddys Laboratories Ltd

Mid Cap

Healthcare Sector

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

Dr. Reddy's Laboratories received regulatory approval for generic oral semaglutide, while facing earnings concerns and mixed Q3 results. BofA maintains a Buy rating with a target price increase.

Dr. Reddy's Gains Approval for Generic Semaglutide - 16 Apr, 2026

Dr. Reddy's Laboratories faces challenges after Brazil's ANVISA rejected its semaglutide filing, leading to a 3% stock drop. Analysts maintain mixed views, with Nomura's Buy rating contrasting Citi's Sell recommendation due to competitive pressures and earnings concerns.

Dr. Reddy's Faces Setbacks Amid Market Opportunities - 15 Apr, 2026

Dr. Reddys Laboratories Ltd. experienced a 0.94% increase in stock price, reaching ₹1,202.70, amidst competitive market dynamics in the semaglutide sector.

Dr. Reddys Lab Sees Positive Stock Performance - 09 Apr, 2026

Morgan Stanley maintains an Equal Weight rating on Dr. Reddy's Laboratories, lowering the target price to ₹1,259 from ₹1,285 due to earnings downgrades. FY26 EPS is cut by 10.7%, with a projected 21% revenue decline in North America from gRevlimid phase-out. Margins are expected to be between 21-22.6%, with recovery anticipated from FY28 driven by semaglutide and biosimilars.

Morgan Stanley Adjusts Target Price for Dr. Reddy's - 08 Apr, 2026

Dr. Reddy’s Laboratories has rebranded Olymviq to Olymra to resolve a dispute with Ozempic's manufacturer. Additionally, the company launched Obeda, India's first generic semaglutide, while reporting a 4.4% revenue increase in Q3FY26, despite a 14% drop in net profit.

Dr. Reddy’s Rebrands and Launches New Product - 31 Mar, 2026

The Delhi High Court has directed Dr. Reddy's Laboratories to stop sales and expansion of its diabetes drug Olymviq amid a trademark dispute with Novo Nordisk, citing phonetic similarities with Ozempic. The court's decision raises concerns over potential consumer confusion.

Dr. Reddy's Halted from Selling Olymviq Drug - 25 Mar, 2026

Dr. Reddy's Laboratories plans to consider Q4 results on May 12. The company also updated its disclosure code and launched diabetes drugs significantly cheaper than competitors.

Dr. Reddy's Updates Disclosure Code and Launches Drugs - 24 Mar, 2026

Dr. Reddy's Laboratories is pivoting towards innovation-led growth, as highlighted by G.V. Prasad. The stock is rated Buy with a target price of Rs 1,600, indicating a potential upside.

Dr. Reddy's Laboratories Focuses on Innovation and Growth - 23 Mar, 2026

Dr Reddys Laboratories launched Obeda®, a semaglutide injection for Type 2 Diabetes, while reporting a decline in Q3 FY26 net profit despite revenue growth. The stock shows bullish momentum.

Dr Reddys Launches Obeda and Reports Q3 Results - 21 Mar, 2026

Dr. Reddy's Laboratories is among several companies preparing to launch semaglutide generics. Initial launches are expected soon, but aggressive pricing may squeeze margins.

Semaglutide Generics Launch Impacting Market Dynamics - 19 Mar, 2026

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

Mutual Funds have increased holdings from 13.31% to 13.87% in Dec 2025 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Up

Promoters holdings remained unchanged at 26.64% of holdings in Dec 2025 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Unchanged

Revenue is down for the last 2 quarters, 9.15K Cr → 9.02K Cr (in ₹), with an average decrease of 1.5% per quarter

This section gives you an insight into how the revenue of the company has moved for the last few quarters.

Revenue Fall

Foreign Institutions have decreased holdings from 24.69% to 22.34% in Dec 2025 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Down

In the last 1 month, DRREDDY stock has moved down by -4.9%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Dip

Retail Investor have decreased holdings from 9.61% to 9.47% in Dec 2025 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Down

Netprofit is down for the last 4 quarters, 1.59K Cr → 1.20K Cr (in ₹), with an average decrease of 8.7% per quarter

This section gives you an insight into how the profit for the company has been for the last few quarters.

Profit Down

Nifty Healthcare

NIFTY 100

Nifty 200

Nifty100 Quality

BSE Healthcare

Nifty LargeMidcap 250

S&P BSE Low Volatility

Nifty 500

S&P BSE 100 ESG

Nifty100 Low Volatility 30

BSE 200

NIFTY 50

BSE MFG

BSE 500

S&P BSE 100 LargeCap TMC

NIFTY PHARMA

S&P BSE Dividend Stability

Nifty50 Value 20

Nifty100 Eq Weig

BSE 100

S&P BSE SENSEX 50

S&P BSE 250 LargeMidCap

Parag Parikh Flexi Cap Direct Growth

ICICI Prudential Value Fund Direct Plan Growth

Nippon India Large Cap Fund - Direct Plan - Growth Plan

ICICI Prudential Large Cap Fund Direct Plan Growth

Nippon India Pharma Fund - Direct Plan - Growth Plan

Dr Reddys Laboratories Ltd’s net profit fell -14.42% since last year same period to ₹1,209.90Cr in the Q3 2025-2026. On a quarterly growth basis, Dr Reddys Laboratories Ltd has generated -10.18% fall in its net profits since last 3-months.

Dr Reddys Laboratories Ltd Earnings Results

In the quarter ending March 2025, Dr Reddys Laboratories Ltd has declared dividend of ₹8.00 per share on 09 May 2025 - translating a dividend yield of 0.66%.

Name	Value	Action
MACD level (12,26)	0.92	Bullish
CCI (20)	-242.04	Bullish
RSI (14)	76.03	Bearish
Momentum (10)	2.5	Bearish
ADI (14)	19.29	Neutral
Ultimate Oscillator (7,14,28)	92.72	Bullish

Name	Value	Action
SMA (20)	1229.19	Bullish
EMA (20)	1229.52	Bullish
VWMA (20)	1229.78	Bullish
SMA (50)	1227.9	Bullish
EMA (50)	1228.03	Bullish
SMA (200)	1223.52	Bullish
EMA (200)	1224.74	Bullish
KAMA (200)	1228.93	Bullish
DEMA (200)	1226.89	Bullish

Dr Reddys Laboratories Ltd (DRREDDY)

Summary

Overall

Oscillators

Moving Averages